CDK1 and hepatocellular carcinoma: Future studies should further develop highly efficient and low-toxicity CDK1 inhibitors and strengthen the interface between preclinical studies and clinical trials to promote the widespread application of CDK1 inhibitors in the treatment of liver fibrosis and hepatocellular carcinoma.